Everest Medicines (HKEX:1952.HK) has announced that its licensing partner, Venatorx Pharmaceuticals, reported positive results from a Phase 3 study investigating the use of cefepime-taniborbactam in hospitalized adults with complicated urinary tract infections (cUTI), including acute pyelonephritis. The study pitted cefepime-taniborbactam against meropenem. First approved in 1996, meropenem is used to treat various bacterial infections. In the…